Association of Circulating Level of High Mobility Group Box 1 With Disease Activity in Antineutrophil Cytoplasmic Autoantibody–Associated Vasculitis
Article first published online: 28 OCT 2013
Copyright © 2013 by the American College of Rheumatology
Arthritis Care & Research
Volume 65, Issue 11, pages 1828–1834, November 2013
How to Cite
Wang, C., Gou, S.-J., Chang, D.-Y., Yu, F., Zhao, M.-H. and Chen, M. (2013), Association of Circulating Level of High Mobility Group Box 1 With Disease Activity in Antineutrophil Cytoplasmic Autoantibody–Associated Vasculitis. Arthritis Care Res, 65: 1828–1834. doi: 10.1002/acr.22187
- Issue published online: 28 OCT 2013
- Article first published online: 28 OCT 2013
- Manuscript Accepted: 23 MAY 2013
- Manuscript Received: 2 DEC 2012
- Chinese 973 Project. Grant Number: 2012CB517702
- Research Fund for the Doctoral Program of Higher Education of China. Grant Number: 20120001110018
- National Key Technology Research and Development Program of the Ministry of Science and Technology of China. Grant Number: 2011BAI10B04
- National Natural Science Fund. Grant Number: 81300599
High mobility group box 1 (HMGB-1), a kind of proinflammatory mediator, is associated with inflammatory conditions and tissue damage. Previous studies have reported that circulating HMGB-1 levels in patients with active antineutrophil cytoplasmic autoantibody (ANCA)–associated vasculitis (AAV) were associated with renal manifestations and burdens of granulomatous inflammation. The current study aimed to investigate whether circulating HMGB-1 levels were associated with disease activity in AAV.
Plasma samples from 74 patients with AAV in active stage and 65 patients with AAV in remission were collected. The plasma levels of HMGB-1 were determined by enzyme-linked immunosorbent assay. Associations between plasma levels of HMGB-1 with clinical and pathologic parameters were analyzed.
Plasma levels of HMGB-1 in active AAV patients were significantly higher than those in normal controls and AAV patients in remission (median 6.11 [interquartile range (IQR) 3.25–12.79] ng/ml versus median 1.12 [IQR 0.53–1.39] ng/ml, P< 0.001; median 6.11 [IQR 3.25–12.79] ng/ml versus median 3.04 [IQR 1.97–4.63] ng/ml, P < 0.001, respectively). Correlation analysis showed that plasma levels of HMGB-1 correlated with initial serum creatinine (r = 0.275, P = 0.018), estimated glomerular filtration rate (r = −0.277, P = 0.017), the Birmingham Vasculitis Activity Score (r = 0.308, P = 0.008), and C-reactive protein level (r = 0.309, P = 0.008). Among the patients with myeloperoxidase (MPO)–ANCA, those within the first quartile of plasma HMGB-1 levels had a significantly lower level of MPO-ANCA than those within the other 3 quartiles.
Circulating HMGB-1 levels might reflect the disease activity and renal involvement of AAV vasculitis.